Greg Rosenn
Neurology with Special Qualifications in Child Neurology · Plainview, NYNPI 1598707697
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,450 of the $33,918 with a category attached, or 60.3%. 23 manufacturers reported payments, led by Tris Pharma Inc at 49.0% of the total. Reporting peaked in 2021 at $12,254 and has fallen 86.3% since, to $1,679 in 2025. Among neurology with special qualifications in child neurology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 766 payments — averaging $44.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$17K
- Supernus Pharmaceuticals, Inc.$9K
- Neurelis, Inc.$1K
- Ironshore Pharmaceuticals Inc.$1K
- Neos Therapeutics, LP$1K
- UCB, Inc.$917
- plus $4K from 17 others
What the payments were for
- Speaking & faculty fees$20,45060%
- Travel & lodging$1,0383%
- Food & beverage$12,40937%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 114 | $16,627 |
| Supernus Pharmaceuticals, Inc. | 256 | $9,018 |
| Neurelis, Inc. | 43 | $1,243 |
| Ironshore Pharmaceuticals Inc. | 55 | $1,189 |
| Neos Therapeutics, LP | 85 | $1,146 |
| UCB, Inc. | 37 | $917 |
| Corium, LLC | 41 | $902 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $691 |
| Vertical Pharmaceuticals, LLC | 23 | $433 |
| Collegium Pharmaceutical, Inc. | 12 | $328 |
| Jazz Pharmaceuticals Inc. | 5 | $327 |
| Greenwich Biosciences, Inc. | 15 | $319 |
| Adlon Therapeutics L.p. | 14 | $274 |
| Sunovion Pharmaceuticals Inc. | 13 | $194 |
| Cranial Technologies, Inc | 4 | $68 |
| Biomarin Pharmaceutical Inc. | 3 | $66 |
| Aquestive Therapeutics, Inc. | 3 | $52 |
| Cognoa, Inc. | 1 | $31 |
| Shire North American Group Inc | 1 | $21 |
| Avion Pharmaceuticals | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Zogenix Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dyanavel XR$14,883
- Quillichew ER$10,396
- Quillivant$9,396
- QELBREE$5,059
- Quillivant XR$1,000
- Epidiolex$243
- VALTOCO$124
- JORNAY PM$119
How this compares
$33,918 in reported general payments places this provider in the 90th percentile of 161 neurology with special qualifications in child neurology providers in New York.
See all neurology with special qualifications in child neurology providers in New York →
Other neurology with special qualifications in child neurology in Plainview
- Claudia ChiribogaNew York$220K
- Eric SegalN White Plains$133K
- Kaleb YohayNew York$125K
- Heather LauNew York$103K
- Louis ManganasEast Setauket$86K
- Darryl DevivoNew York$67K
- Mary Lynn ChuNew York$66K
- Jonathan MinkRochester$54K
- Sanjeev KothareNew Hyde Park$53K
- Mohammad QasaymehAmherst$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.